S X Tang1, J J Yi2, M E Calkins1, D A Whinna1, C G Kohler1, M C Souders3, D M McDonald-McGinn3, E H Zackai3, B S Emanuel3, R C Gur1, R E Gur1. 1. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2. Department of Child and Adolescent Psychiatry, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 3. Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Abstract
BACKGROUND: Chromosome 22q11.2 deletion syndrome (22q11DS) is a common genetic disorder with high rates of psychosis and other psychopathologies, but few studies discuss treatment. Our aim was to characterize the prevalence and treatment of major psychiatric illnesses in a well-characterized sample of individuals with 22q11DS. METHOD: This was a cross-sectional study of 112 individuals aged 8 to 45 years with a confirmed diagnosis of 22q11DS. Each participant was administered a modified Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS) and the Structured Interview for Prodromal Syndromes (SIPS). Phenotypes assessed were threshold and subthreshold psychosis, depression, mania, generalized and separation anxiety, obsessions/compulsions, inattention/hyperactivity and substance use. Histories of mental health care and current psychotropic treatment were obtained. RESULTS: Psychopathology was common, with 79% of individuals meeting diagnostic criteria for a disorder at the time of assessment. Diagnoses of psychosis were made in 11% of cases, attenuated positive symptom syndrome (APS) in 21%, and 47% experienced significant subthreshold symptoms. Peak occurrence of psychosis risk was during adolescence (62% of those aged 12-17 years). Criteria for a mood disorder were met by 14%, for anxiety disorder 34% and for attention deficit hyperactivity disorder (ADHD) 31%. Mental health care had been received by 63% of individuals in their lifetime, but only 40% continued therapy and 39% used psychotropics. Antipsychotics were used by 42% of participants with psychosis and none of the participants with APS. Half of those at risk for psychosis were receiving no mental health care. CONCLUSIONS: Psychopathology is common in 22q11DS but is not adequately treated or clinically followed. Particular attention should be paid to subthreshold psychotic symptoms, especially in adolescents.
BACKGROUND: Chromosome 22q11.2 deletion syndrome (22q11DS) is a common genetic disorder with high rates of psychosis and other psychopathologies, but few studies discuss treatment. Our aim was to characterize the prevalence and treatment of major psychiatric illnesses in a well-characterized sample of individuals with 22q11DS. METHOD: This was a cross-sectional study of 112 individuals aged 8 to 45 years with a confirmed diagnosis of 22q11DS. Each participant was administered a modified Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS) and the Structured Interview for Prodromal Syndromes (SIPS). Phenotypes assessed were threshold and subthreshold psychosis, depression, mania, generalized and separation anxiety, obsessions/compulsions, inattention/hyperactivity and substance use. Histories of mental health care and current psychotropic treatment were obtained. RESULTS: Psychopathology was common, with 79% of individuals meeting diagnostic criteria for a disorder at the time of assessment. Diagnoses of psychosis were made in 11% of cases, attenuated positive symptom syndrome (APS) in 21%, and 47% experienced significant subthreshold symptoms. Peak occurrence of psychosis risk was during adolescence (62% of those aged 12-17 years). Criteria for a mood disorder were met by 14%, for anxiety disorder 34% and for attention deficit hyperactivity disorder (ADHD) 31%. Mental health care had been received by 63% of individuals in their lifetime, but only 40% continued therapy and 39% used psychotropics. Antipsychotics were used by 42% of participants with psychosis and none of the participants with APS. Half of those at risk for psychosis were receiving no mental health care. CONCLUSIONS: Psychopathology is common in 22q11DS but is not adequately treated or clinically followed. Particular attention should be paid to subthreshold psychotic symptoms, especially in adolescents.
Authors: Aravindhan Veerapandiyan; Omar A Abdul-Rahman; Margaret P Adam; Michael J Lyons; Melanie Manning; Karlene Coleman; Lisa Kobrynski; Deeksha Taneja; Kelly Schoch; Holly H Zimmerman; Vandana Shashi Journal: Am J Med Genet A Date: 2011-08-10 Impact factor: 2.802
Authors: Anne S Bassett; Donna M McDonald-McGinn; Koen Devriendt; Maria Cristina Digilio; Paula Goldenberg; Alex Habel; Bruno Marino; Solveig Oskarsdottir; Nicole Philip; Kathleen Sullivan; Ann Swillen; Jacob Vorstman Journal: J Pediatr Date: 2011-05-12 Impact factor: 4.406
Authors: Kevin M Antshel; Robert Shprintzen; Wanda Fremont; Anne Marie Higgins; Stephen V Faraone; Wendy R Kates Journal: J Am Acad Child Adolesc Psychiatry Date: 2010-04 Impact factor: 8.829
Authors: Ronald J Wapner; Christa Lese Martin; Brynn Levy; Blake C Ballif; Christine M Eng; Julia M Zachary; Melissa Savage; Lawrence D Platt; Daniel Saltzman; William A Grobman; Susan Klugman; Thomas Scholl; Joe Leigh Simpson; Kimberly McCall; Vimla S Aggarwal; Brian Bunke; Odelia Nahum; Ankita Patel; Allen N Lamb; Elizabeth A Thom; Arthur L Beaudet; David H Ledbetter; Lisa G Shaffer; Laird Jackson Journal: N Engl J Med Date: 2012-12-06 Impact factor: 91.245
Authors: Edith M Jolin; Ronald A Weller; Naushad R Jessani; Elaine H Zackai; Donna M McDonald-McGinn; Elizabeth B Weller Journal: J Affect Disord Date: 2009-03-09 Impact factor: 4.839
Authors: Cynthia B Solot; Tyler M Moore; Terrence Blaine Crowley; Marsha Gerdes; Edward Moss; Daniel E McGinn; Beverly S Emanuel; Elaine H Zackai; Sean Gallagher; Monica E Calkins; Kosha Ruparel; Ruben C Gur; Donna M McDonald-McGinn; Raquel E Gur Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2020-07-27 Impact factor: 3.568
Authors: Sunny X Tang; James J Yi; Tyler M Moore; Monica E Calkins; Christian G Kohler; Daneen A Whinna; Margaret C Souders; Elaine H Zackai; Donna M McDonald-McGinn; Beverly S Emanuel; Warren B Bilker; Ruben C Gur; Raquel E Gur Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-06-19 Impact factor: 8.829
Authors: Ehud Mekori-Domachevsky; Yael Guri; James Yi; Omri Weisman; Monica E Calkins; Sunny X Tang; Raz Gross; Donna M McDonald-McGinn; Beverly S Emanuel; Elaine H Zackai; Gil Zalsman; Abraham Weizman; Ruben C Gur; Raquel E Gur; Doron Gothelf Journal: Schizophr Res Date: 2016-12-29 Impact factor: 4.939
Authors: Mariken B de Koning; Esther D A van Duin; Erik Boot; Oswald J N Bloemen; Jaap A Bakker; Kathryn M Abel; Thérèse A M J van Amelsvoort Journal: Psychopharmacology (Berl) Date: 2015-06-12 Impact factor: 4.530
Authors: Ania M Fiksinski; Maude Schneider; Clodagh M Murphy; Marco Armando; Stefano Vicari; Jaume M Canyelles; Doron Gothelf; Stephan Eliez; Elemi J Breetvelt; Celso Arango; Jacob A S Vorstman Journal: Am J Med Genet A Date: 2018-09-08 Impact factor: 2.802
Authors: Christian Kohler; Karin E Borgmann-Winter; Irene Hurford; Eli Neustadter; James Yi; Monica E Calkins Journal: Curr Psychiatry Rep Date: 2014-04 Impact factor: 5.285
Authors: David R Roalf; J Eric Schmitt; Simon N Vandekar; Theodore D Satterthwaite; Russell T Shinohara; Kosha Ruparel; Mark A Elliott; Karthik Prabhakaran; Donna M McDonald-McGinn; Elaine H Zackai; Ruben C Gur; Beverly S Emanuel; Raquel E Gur Journal: Psychiatry Res Neuroimaging Date: 2017-08-24 Impact factor: 2.376